Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 41 clinical trials
NBE-002 in Patients With Advanced Solid Tumors

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1 antibody-drug conjugate, in patients with advanced solid tumors.

blood coagulation tests
anthracycline
triple-negative breast cancer
measurable disease
systemic therapy
  • 0 views
  • 19 Feb, 2024
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: Sacituzumab govitecan (IMMU-132) Pembrolizumab (Keytruda; MK-3475)

brain metastasis
immunohistochemistry
adjuvant
alopecia
neuropathy
  • 8 views
  • 19 Feb, 2024
Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: Ipatasertib Atezolizumab

immunohistochemistry
adjuvant
axillary lymph node dissection
hba1c
ipatasertib
  • 0 views
  • 19 Feb, 2024
Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer

Comparing preventive effect of myocardial global longitudinal strain-based cardioprotective stragety (angiotensin receptor blocker prophylaxis) with left ventricular ejection fraction-based strategy in breast cancer patients treated with adjuvant trastuzumab.

her2/neu-positive breast cancer
adjuvant
immunomodulators
anthracycline
immunostimulant
  • 0 views
  • 19 Feb, 2024
reatment Standards and Outcomes of Patients With ER/PR Positive HER2-negative Metastatic Breast Cancer

To capture the treatment patterns and clinical characteristics of patients with ER/PR positive, HER2-negative MBC in Greece

HER2
breast cancer
cancer
stage iv breast cancer
  • 0 views
  • 19 Feb, 2024
Concordance of the IHC4 Score Performed in Local or Central Laboratory to Endopredict in ER+/HER2- Breast Cancer

Retrospective observational, multicentric study assessing the immunohistochemistry (IHC) based test IHC4 score in infiltrating early breast cancer: comparison of the score performed in local laboratory vs in a central laboratory and concordance with a molecular gold standard classifier (EndoPredict).

ffpe
immunohistochemistry
cancer
invasive breast cancer
er-positive breast cancer
  • 0 views
  • 19 Feb, 2024
Real-life Pan-HER-blockade With Neratinib

So far, there is no data available on treatment of patients with early-stage hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2)-overexpressed/amplified breast cancer, who completed adjuvant trastuzumab-based therapy less than one year ago, in the clinical routine setting.

adjuvant
immunostimulant
human epidermal growth factor
erbb2
breast neoplasm
  • 0 views
  • 19 Feb, 2024
Clip Marker Placement in Primary Lesions of Breast Cancer Patients Receiving Neoadjuvant Therapy

The present prospective registry study aims to evaluate how often the intramammary Tumark Vision clip can be detected by ultrasound after completion of NST in patients with TNBC and HER2+ breast cancer and thus, in the case of pCR, how often the elaborate clipping with mammographic (stereotactic) guidance can be …

  • 0 views
  • 19 Feb, 2024
A Clinical Study of Pyrotinib in Patients of Advanced Colorectal Cancer With Her2 Variation

To Observe the Efficacy and Safety of Pyrotinib Maleate in Patients With Advanced HER2 Variation Colorectal Cancer

neutrophil count
metastasis
pyrotinib
immunohistochemistry
ejection fraction
  • 0 views
  • 19 Feb, 2024
Cancer Therapy Effects on the Heart

Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) is commonly given to treat pediatric cancer, and carries a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to …

metastasis
daunorubicin
heart failure
cancer treatment
anthracycline
  • 0 views
  • 19 Feb, 2024